5 Most Active Penny Stocks to Buy

In this article, we will list the 5 Most Active Penny Stocks to Buy. Please visit 10 Most Active Penny Stocks to Buy if you’d like to see an extended list and how we came up with the list of most active penny stocks to buy.

5. Nuvation Bio Inc. (NYSE:NUVB)

Nuvation Bio Inc. (NYSE:NUVB) is one of the 10 most active penny stocks to buy.

As of March 16, 2026, Wall Street remains optimistic about Nuvation Bio Inc. (NYSE:NUVB).

With over 90% of analysts covering Nuvation Bio Inc. (NYSE:NUVB) maintaining bullish ratings, the consensus price target is $12.00, indicating a potential upside of 166.67%.

As investors focus on IBTROZI’s commercial launch and the company’s growing oncology pipeline, sentiment remains positive. Moreover, analyst confidence has been bolstered by Nuvation Bio Inc. (NYSE:NUVB)’s early commercialization progress.

Copyright: wrangel / 123RF Stock Photo

Consequently, RBC Capital analysts increased the firm’s price target from $12.00 to $13.00 and reaffirmed their “Outperform” rating for Nuvation Bio Inc. (NYSE:NUVB) on March 3, 2026. They highlighted the long-term potential across the company’s oncology pipeline and the strong physician adoption of IBTROZI.

According to Nuvation Bio Inc.’s (NYSE:NUVB) March 2, 2026, fourth-quarter earnings release, IBTROZI generated $15.70 million in net product revenue in Q4, with 216 new patients starting treatment. A $25.00 million milestone payment from Nippon Kayaku was the main driver of the company’s $26.20 million collaboration and license revenue, helping its cash and equivalents reach $529.20 million as of December 31, 2025. Nuvation Bio reported a net loss of $36.6 million, or $(0.11) per share. The net loss for the comparable period in 2024 was $49.4 million, or $0.15 per share.

Nuvation Bio Inc. (NYSE:NUVB) is a biopharmaceutical company developing new treatments for difficult-to-treat cancers. The company was founded by David Hung in 2018, and its headquarters are in New York City.